Published in J Virol on October 01, 2002
Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci U S A (2004) 1.38
Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res (2010) 1.29
Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C. J Virol (2004) 1.14
Molecular mechanisms of FIV infection. Vet Immunol Immunopathol (2008) 1.02
Feline immunodeficiency virus ORF-Ais required for virus particle formation and virus infectivity. J Virol (2003) 0.95
SAMHD1 specifically restricts retroviruses through its RNase activity. Retrovirology (2015) 0.94
Transcriptional regulation of latent feline immunodeficiency virus in peripheral CD4+ T-lymphocytes. Viruses (2012) 0.93
RNA secondary structure of the feline immunodeficiency virus 5'UTR and Gag coding region. Nucleic Acids Res (2008) 0.90
Feline immunodeficiency virus envelope glycoproteins antagonize tetherin through a distinctive mechanism that requires virion incorporation. J Virol (2014) 0.90
Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology (2007) 0.88
Cellular restriction factors of feline immunodeficiency virus. Viruses (2011) 0.81
Feline immunodeficiency virus latency. Retrovirology (2013) 0.81
OrfA downregulates feline immunodeficiency virus primary receptor CD134 on the host cell surface and is important in viral infection. J Virol (2010) 0.80
Construction and testing of orfA +/- FIV reporter viruses. Viruses (2012) 0.77
Evolution of puma lentivirus in bobcats (Lynx rufus) and mountain lions (Puma concolor) in North America. J Virol (2014) 0.77
Accessory genes confer a high replication rate to virulent feline immunodeficiency virus. J Virol (2013) 0.77
Evolution of the long terminal repeat and accessory genes of feline immunodeficiency virus genomes from naturally infected cougars. Virology (2007) 0.76
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res (1983) 124.30
Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47
Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J Mol Biol (1986) 55.34
Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell (1986) 42.45
Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs. Nucleic Acids Res (1984) 39.52
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res (1987) 36.83
Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J Mol Biol (1978) 33.47
Empirical predictions of protein conformation. Annu Rev Biochem (1978) 25.48
Prediction of protein conformation. Biochemistry (1974) 20.51
Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucleic Acids Res (1981) 18.27
GAL4-VP16 is an unusually potent transcriptional activator. Nature (1988) 16.53
Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. Biochemistry (1974) 12.07
Eukaryotic gene transcription with purified components. Methods Enzymol (1983) 9.71
Transcription activation by the adenovirus E1a protein. Nature (1989) 9.08
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
A simple phase-extraction assay for chloramphenicol acyltransferase activity. Gene (1988) 8.40
A vector for expressing GAL4(1-147) fusions in mammalian cells. Nucleic Acids Res (1989) 8.06
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell (1989) 6.28
Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 4.57
Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites. Mol Cell Biol (2000) 3.57
Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J (1999) 3.50
Comparison of two host cell range variants of feline immunodeficiency virus. J Virol (1990) 2.98
Recognition of AUG and alternative initiator codons is augmented by G in position +4 but is not generally affected by the nucleotides in positions +5 and +6. EMBO J (1997) 2.96
Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature (1994) 2.87
Isolation of RD-114-like oncornavirus from a cat cell line. J Virol (1973) 2.61
PCR-ligation-PCR mutagenesis: a protocol for creating gene fusions and mutations. Biotechniques (1995) 2.39
Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci U S A (2000) 2.32
Conformational properties of amino acid residues in globular proteins. J Mol Biol (1976) 1.93
The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site. J Virol (2001) 1.87
A calcium-dependent antibody for identification and purification of recombinant proteins. Biotechniques (1989) 1.86
cis- and trans-acting transcriptional regulation of visna virus. Science (1985) 1.74
Expansion of CREB's DNA recognition specificity by Tax results from interaction with Ala-Ala-Arg at positions 282-284 near the conserved DNA-binding domain of CREB. Proc Natl Acad Sci U S A (1994) 1.57
Binding of recombinant feline immunodeficiency virus surface glycoprotein to feline cells: role of CXCR4, cell-surface heparans, and an unidentified non-CXCR4 receptor. J Virol (2001) 1.54
Alternative translation initiation of the Moloney murine leukemia virus mRNA controlled by internal ribosome entry involving the p57/PTB splicing factor. J Biol Chem (1995) 1.54
Regulation of gene expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology (1992) 1.42
Binding of the HTLV-I Tax1 transactivator to the inducible 21 bp enhancer is mediated by the cellular factor HEB1. EMBO J (1991) 1.37
An internal ribosome entry segment promotes translation of the simian immunodeficiency virus genomic RNA. J Biol Chem (2000) 1.37
Regulation of gene expression by HTLV-I Tax protein. Methods (1998) 1.28
Mutational analysis of the equine infectious anemia virus Tat-responsive element. J Virol (1991) 1.28
Primer extension analysis of eukaryotic ribosome-mRNA complexes. Nucleic Acids Res (1998) 1.26
Translation of equine infectious anemia virus bicistronic tat-rev mRNA requires leaky ribosome scanning of the tat CTG initiation codon. J Virol (1993) 1.26
Influence of ORF2 on host cell tropism of feline immunodeficiency virus. Virology (1996) 1.21
Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity. J Virol (1999) 1.18
Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J Virol (2000) 1.07
Chimeric proteins composed of Jun and CREB define domains required for interaction with the human T-cell leukemia virus type 1 Tax protein. J Virol (1995) 1.06
FIV infection of IL-2-dependent and -independent feline lymphocyte lines: host cells range distinctions and specific cytokine upregulation. Vet Immunol Immunopathol (1998) 0.98
Cis- and trans-regulation of feline immunodeficiency virus: identification of functional binding sites in the long terminal repeat. J Gen Virol (1994) 0.97
Characterization of an internal ribosomal entry segment in the 5' leader of murine leukemia virus env RNA. J Virol (2000) 0.96
Molecular analysis of the feline immunodeficiency virus protease: generation of a novel form of the protease by autoproteolysis and construction of cleavage-resistant proteases. J Virol (1997) 0.94
A new regulatory element that augments the Tax-dependent enhancer of human T-cell leukemia virus type 1 and cloning of cDNAs encoding its binding proteins. J Virol (1993) 0.92
Feline immunodeficiency virus Vif localizes to the nucleus. J Virol (2000) 0.90
Visna virus Tat protein: a potent transcription factor with both activator and suppressor domains. J Virol (1994) 0.89
Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses. J Virol (2001) 0.86
Feline immunodeficiency virus gene expression: analysis of the RNA splicing pattern and the monocistronic rev mRNA. J Gen Virol (1993) 0.85
Targeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo. J Virol (1999) 0.84
Inhibitors of HIV-1 protease by using in situ click chemistry. Angew Chem Int Ed Engl (2006) 1.63
Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc Natl Acad Sci U S A (2004) 1.38
Conformational flexibility in the flap domains of ligand-free HIV protease. Acta Crystallogr D Biol Crystallogr (2007) 1.36
1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors. Chembiochem (2005) 1.27
A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs. J Biol Chem (2005) 1.23
Structural mapping of CD134 residues critical for interaction with feline immunodeficiency virus. Nat Struct Mol Biol (2004) 1.16
Is resistance futile? Curr Drug Targets Infect Disord (2003) 1.14
Characterization of a highly pathogenic molecular clone of feline immunodeficiency virus clade C. J Virol (2004) 1.14
Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors. Chembiochem (2003) 1.13
Robust expression of a bioactive mammalian protein in Chlamydomonas chloroplast. Plant Biotechnol J (2007) 1.09
Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope. J Virol (2006) 1.08
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. Retrovirology (2006) 1.08
Specific interaction of feline immunodeficiency virus surface glycoprotein with human DC-SIGN. J Virol (2004) 1.07
Factors that increase the effective concentration of CXCR4 dictate feline immunodeficiency virus tropism and kinetics of replication. J Virol (2004) 1.05
Molecular mechanisms of FIV infection. Vet Immunol Immunopathol (2008) 1.02
Human immunodeficiency virus type 1 and influenza virus exit via different membrane microdomains. J Virol (2007) 1.00
Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3. Retrovirology (2004) 0.97
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J Virol (2003) 0.97
Small molecule regulation of protein conformation by binding in the Flap of HIV protease. ACS Chem Biol (2013) 0.94
Replication properties of clade A/C chimeric feline immunodeficiency viruses and evaluation of infection kinetics in the domestic cat. J Virol (2008) 0.94
Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3. J Mol Biol (2005) 0.93
A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant. J Med Chem (2008) 0.92
Defining HIV-1 protease substrate selectivity. Curr Drug Targets Infect Disord (2002) 0.91
Mapping of the CXCR4 binding site within variable region 3 of the feline immunodeficiency virus surface glycoprotein. J Virol (2008) 0.89
Crystallographic fragment-based drug discovery: use of a brominated fragment library targeting HIV protease. Chem Biol Drug Des (2013) 0.88
Feline immunodeficiency virus OrfA alters gene expression of splicing factors and proteasome-ubiquitination proteins. Virology (2007) 0.88
Borna disease virus requires cholesterol in both cellular membrane and viral envelope for efficient cell entry. J Virol (2009) 0.87
Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system. J Virol (2006) 0.87
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3. Retrovirology (2007) 0.87
Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3. J Virol (2004) 0.87
Identification of broad-based HIV-1 protease inhibitors from combinatorial libraries. Biochem J (2010) 0.87
Identification of amino acid residues important for heparan sulfate proteoglycan interaction within variable region 3 of the feline immunodeficiency virus surface glycoprotein. J Virol (2011) 0.85
Fine definition of the CXCR4-binding region on the V3 loop of feline immunodeficiency virus surface glycoprotein. PLoS One (2010) 0.85
Pathogenicity and rapid growth kinetics of feline immunodeficiency virus are linked to 3' elements. PLoS One (2011) 0.81
Generation of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease. J Virol (2010) 0.81
Nicotine prevents HIVgp120-caused electrophysiological and motor disturbances in rats. Neurosci Lett (2005) 0.80
OrfA downregulates feline immunodeficiency virus primary receptor CD134 on the host cell surface and is important in viral infection. J Virol (2010) 0.80
Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases. Bioorg Med Chem (2003) 0.80
Early detection of neuropathophysiology using diffusion-weighted magnetic resonance imaging in asymptomatic cats with feline immunodeficiency viral infection. J Neurovirol (2011) 0.80
Improved health and survival of FIV-infected cats is associated with the presence of autoantibodies to the primary receptor, CD134. Proc Natl Acad Sci U S A (2009) 0.79
Epoxide opening in water and screening in situ for rapid discovery of enzyme inhibitors in microtiter plates. Bioorg Med Chem (2005) 0.78
Structural basis for drug and substrate specificity exhibited by FIV encoding a chimeric FIV/HIV protease. Acta Crystallogr D Biol Crystallogr (2011) 0.78
Accessory genes confer a high replication rate to virulent feline immunodeficiency virus. J Virol (2013) 0.77
Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection. Retrovirology (Auckl) (2012) 0.77
Domestic cat microsphere immunoassays: detection of antibodies during feline immunodeficiency virus infection. J Immunol Methods (2013) 0.75
Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitors. J Virol (2013) 0.75
Prolonged waking reduces human immunodeficiency virus glycoprotein 120- or tumor necrosis factor alpha-induced apoptosis in the cerebral cortex of rats. Neurosci Lett (2004) 0.75